Journal article
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
Abstract
BACKGROUND AND AIMS: This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine.
METHODS: In this phase 3b/4, open-label, multicentre, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8g/day once daily for 8 weeks [induction …
Authors
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D’Haens G; Group OBOTUCRS
Journal
Journal of Crohn's and Colitis, Vol. 10, No. 8, pp. 925–933
Publisher
Oxford University Press (OUP)
Publication Date
August 2016
DOI
10.1093/ecco-jcc/jjw049
ISSN
1197-4982
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalColitis, UlcerativeDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansInduction ChemotherapyMaintenance ChemotherapyMaleMesalamineMiddle AgedProspective StudiesTreatment OutcomeYoung Adult